Comparison of onabotulinumtoxina utilization across various etiologies of spasticity from the Adult spasticity international registry study: ASPIRE - 15/07/18
, D.S. Bandari 2, G. Bavikatte 3, W.H. Jost 4, A. Zuzek 5, E. McCusker 6, A. Patel 7, J. Largent 8, A. Esquenazi 9
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Résumé |
Introduction/Background |
Etiology-specific differences in onabotulinumtoxin A utilization to treat spasticity are largely unknown. Real-world clinical practice data from the ASPIRE study may help optimize onabotulinumtoxin A treatment for spasticity. Our objective is to evaluate real-world utilization of onabotulinumtoxin A for spasticity caused by various etiologies.
Material and method |
1-year interim analysis; international, multicenter, prospective, observational study (NCT01930786) examining adult patients with spasticity across etiologies. Patients were treated with onabotulinumtoxin A at the physician's discretion; utilization patterns were recorded at each visit.
Results |
A total of 731 patients received≥1 onabotulinumtoxinA treatment; 37% of patients were naïve to botulinum toxins for spasticity. The most common etiology was stroke (n=411/731, 56%), followed by multiple sclerosis (MS; n=119/731, 16%), cerebral palsy (CP; n=77/731, 11%), traumatic brain injury (TBI; n=45/731, 6%), spinal cord injury (SCI; n=42/731, 6%), and other (n=72/731). Across etiologies (n=731), total onabotulinumtoxin A doses per treatment session ranged from 45–1038 U. The most frequently treated lower limb presentations, with mean doses injected per presentation, varied by etiology. Stroke: equinovarus foot (223 U [SD=131]), flexed toe (64 U [SD=51]), and flexed knee (143 U [SD=86]); MS: equinovarus foot (206 U [SD=124]), stiff extended knee (155 U [SD=134]), and adducted thigh (173 U [SD=112]); CP: equinovarus foot (162 U [SD=116]), flexed knee (150 U [SD=89]), and adducted thigh (163 U [SD=94]); TBI: equinovarus foot (223 U [SD=109]), flexed toe (89 U [SD=61]), and flexed knee (154 U [SD=60]); and SCI: equinovarus foot (277 U [SD=168]), adducted thigh (140U [SD=66]), and flexed knee (165 U [SD=84]). In the overall population (n=731), adverse events (AEs) were reported by 28.9% of patients, with 2.3% of events considered treatment-related. Serious AEs were reported by 10.3% of patients, with 0.3% of events considered treatment-related. No new safety signals were identified.
Conclusion |
Real-world 1-year interim data from ASPIRE captured etiology-specific utilization of onabotulinumtoxin A for spasticity in clinical practice, while further demonstrating safety across etiologies.
Le texte complet de cet article est disponible en PDF.Keywords : Onabotulinumtoxin A, Spasticity, Etiologies
Plan
Vol 61 - N° S
P. e69 - juillet 2018 Retour au numéro
Article précédent
- An examination of real-world onabotulinumtoxina utilization for the treatment of lower limb spasticity: The Adult Spasticity International Registry (ASPIRE) study
- A. Esquenazi, W. Jost, G. Bavikatte, D. Bandari, M. Munin, A. Zuzek, A. Patel, J. Largent, G. Francisco
- Botulinum toxin a in upper limb spasticity management: Baseline data from the upper limb international spasticity (ULIS)–III study
- L. Turner-Stokes, S. Ashford, J. Jacinto, K. Fheodoroff, P. Maisonobe, O. Senturk, A. Brashear
Bienvenue sur EM-consulte, la référence des professionnels de santé.